4,061 results on '"Antonella A"'
Search Results
2. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis
3. Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms
4. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients
5. Donor natural killer cells trigger production of β-2-microglobulin to enhance post–bone marrow transplant immunity
6. Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
7. Unique molecular and functional features of extramedullary hematopoietic stem and progenitor cell reservoirs in humans
8. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
9. Clinical relevance of clonal hematopoiesis in persons aged ≥80 years
10. Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88
11. Single-cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs
12. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity
13. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
14. Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
15. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression
16. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
17. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model
18. Haploidentical hematopoietic transplantation from KIR ligand–mismatched donors with activating KIRs reduces nonrelapse mortality
19. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
20. T Cell Ig and ITIM Domains (TIGIT) Expression in Multiple Myeloma
21. Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study
22. BMP5: a novel tile of the hepcidin regulatory pathway
23. The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes
24. Selective factor VIII activation by the tissue factor–factor VIIa–factor Xa complex
25. Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress
26. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine
27. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
28. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
29. Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches
30. Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation
31. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice
32. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency
33. Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice
34. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
35. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts
36. Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy
37. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
38. Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
39. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies
40. Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial
41. Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
42. Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
43. Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity
44. Expression Profiles of Human Endogenous Retrovirus in Chronic Myeloid Leukemia at Diagnosis and after TKI Therapy
45. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
46. Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms
47. Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience
48. The second transferrin receptor regulates red blood cell production in mice
49. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study
50. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.